TFPI2 and ovarian disorder: AUCs of TFPI2 were higher than those of CA125 in discrimination of patients with early-stage CCC from other ovarian diseases (AUC = 0.835 versus 0.541), borderline ovarian tumors and other EOCs (AUC = 0.776 versus 0.687), and EMS (AUC = 0.879 versus 0.627), suggesting that unlike CA125, TFPI2 could discriminate patients with early-stage CCC and other patient groups.